1887

Abstract

. Identification of the emerging yeast species among presumptively identified Iranian isolates.

. Clinical species complex isolates from blood (=100; 46.9%), vaginal swabs (=20; 9.4%), bronchoalveolar lavage (=10; 4.7%) and sputum (=12; 5.6%) from 68 patients from Iran were investigated. Isolates were characterized by CHROMagar, multiplex PCRs, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), amplified fragment length polymorphism (AFLP) fingerprinting, internal transcribed spacer (ITS)/large subunit (LSU) rDNA and / sequencing, and the European Committee on Antimicrobial Susceptibility Testing broth microdilution method. A comprehensive literature review was conducted and all the relevant clinical and microbiological data were collected.

. Four isolates were recovered from blood samples of three subjects and were all consistently identified by nine-plex PCR, Bruker MALDI-TOF MS, and LSU and ITS rDNA sequencing. AFLP genotyping clustered the isolates into two groups. Sequencing of the and hotspots showed no accountable amino acid substitutions. All isolates were susceptible to amphotericin B, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin and micafungin.

. In total, 4 out of 213 clinical species complex candidemia isolates were . Improvement of the BioMerieux Vitek MS database is required to accurately identify and it is advised to alternatively use CHROMagar and/or PCR-based techniques. As other species within the clade may cause infection and showed high MIC values for antifungals, inclusion of their spectra into the MALDI-TOF MS database seems relevant. Due to developing resistance to fluconazole and insufficient efficacy of caspofungin, the combination of catheter removal plus treatment with caspofungin, or voriconazole, or micafungin might be effective for patients.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000963
2019-05-01
2024-10-03
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/5/770.html?itemId=/content/journal/jmm/10.1099/jmm.0.000963&mimeType=html&fmt=ahah

References

  1. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012; 50:3435–3442 [View Article]
    [Google Scholar]
  2. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58:4690–4696 [View Article]
    [Google Scholar]
  3. Hou X, Xiao M, Chen SCA, Kong F, Wang H et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study. Front Microbiol 2017; 8:1–9 [View Article]
    [Google Scholar]
  4. Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun 2016; 7:11128 [View Article]
    [Google Scholar]
  5. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018; 73:i4–i13 [View Article]
    [Google Scholar]
  6. Alcoba-Flórez J, Méndez-Alvarez S, Cano J, Guarro J, Pérez-Roth E et al. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005; 43:4107–4111 [View Article]
    [Google Scholar]
  7. Correia A, Sampaio P, James S, Pais C. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata . Int J Syst Evol Microbiol 2006; 56:313–317 [View Article]
    [Google Scholar]
  8. Gabaldón T, Martin T, Marcet-Houben M, Durrens P, Bolotin-Fukuhara M et al. Comparative genomics of emerging pathogens in the Candida glabrata clade. BMC Genomics 2013; 14:623 [View Article]
    [Google Scholar]
  9. Arastehfar A, Fang W, Pan W, Liao W, Yan L et al. Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR. BMC Infect Dis 2018; 18:1–9 [View Article]
    [Google Scholar]
  10. Hou X, Xiao M, Chen SCA, Wang H, Yu SY et al. Identification and antifungal susceptibility profiles of Candida nivariensis and Candida bracarensis in a multi-center Chinese collection of yeasts. Front Microbiol 2017; 8:1–8 [View Article]
    [Google Scholar]
  11. Marchetta A, Gerrits van den Ende B, Al-Hatmi AMS, Hagen F, Zalar P et al. Global Molecular Diversity of the Halotolerant Fungus Hortaea werneckii . Life 2018; 8:31 [View Article]
    [Google Scholar]
  12. Arastehfar A, Fang W, Pan W, Lackner M, Liao W et al. Yeast panel multiplex PCR for identification of clinically important yeast species: stepwise Diagnostic strategy, useful for developing countries. Diagn Microbiol Infect Dis 2019; 93:112–119 [View Article]
    [Google Scholar]
  13. Cassagne C, Cella AL, Suchon P, Normand AC, Ranque S et al. Evaluation of four pretreatment procedures for MALDI-TOF MS yeast identification in the routine clinical laboratory. Med Mycol 2013; 51:371–377 [View Article]
    [Google Scholar]
  14. Stielow JB, Lévesque CA, Seifert KA, Meyer W, Iriny L et al. One fungus, which genes? development and assessment of universal primers for potential secondary fungal DNA barcodes. Persoonia 2015; 35:242–263 [View Article]
    [Google Scholar]
  15. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724–1732 [View Article]
    [Google Scholar]
  16. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance. Antimicrob Agents Chemother 2013; 57:6361–6365 [View Article]
    [Google Scholar]
  17. McCarty TP, Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2016; 30:103–124 [View Article]
    [Google Scholar]
  18. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32:S87–S91 [View Article]
    [Google Scholar]
  19. Swoboda-Kopeć E, Sikora M, Golas M, Piskorska K, Gozdowski D et al. Candida nivariensis in comparison to different phenotypes of Candida glabrata . Mycoses 2014; 57:747–753 [View Article]
    [Google Scholar]
  20. Bishop JA, Chase N, Magill SS, Kurtzman CP, Fiandaca MJ et al. Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: susceptibility data and documentation of presumed infection. J Clin Microbiol 2008; 46:443–446 [View Article]
    [Google Scholar]
  21. Byun SA, Won EJ, Kim M et al. Multilocus Sequence Typing (MLST) genotypes of Candida glabrata bloodstream isolates in Korea: association with antifungal resistance, mutations in mismatch repair gene (MSH2), and clinical outcomes. Antimicrob Agents Chemother 2018; 13:1–10
    [Google Scholar]
  22. Fujita S-i, Senda Y, Okusi T, Ota Y, Takada H et al. Catheter-related fungemia due to fluconazole-resistant Candida nivariensis . J Clin Microbiol 2007; 45:3459–3461 [View Article]
    [Google Scholar]
  23. Sharma C, Wankhede S, Muralidhar S, Prakash A, Singh PK et al. Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagn Microbiol Infect Dis 2013; 76:46–50 [View Article]
    [Google Scholar]
  24. Singh A, Healey KR, Yadav P, Upadhyaya G, Sachdeva N et al. Absence of azole or echinocandin resistance in Candida glabrata isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway. Antimicrob Agents Chemother 2018; 62:195–18 [View Article]
    [Google Scholar]
  25. Tay ST, Lotfalikhani A, Sabet NS, Ponnampalavanar S, Sulaiman S et al. Occurrence and characterization of Candida nivariensis from a culture collection of Candida glabrata clinical isolates in Malaysia. Mycopathologia 2014; 178:307–314 [View Article]
    [Google Scholar]
  26. Li J, Shan Y, Fan S, Liu X. Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal candidiasis. Mycopathologia 2014; 178:279–283 [View Article]
    [Google Scholar]
  27. López-Soria LM, Bereciartua E, Santamaría M, Soria LM, Hernández-Almaraz JL et al. Primer caso de fungemia asociada a catéter por Candida nivariensis en la Península Ibérica. Rev Iberoam Micol 2013; 30:69–71 [View Article]
    [Google Scholar]
  28. Shields RK, Kline EG, Healey KR, Kordalewska M, Perlin DS et al. Spontaneous mutational frequency and FKS mutation rates vary by echinocandin agent against Candida glabrata . Antimicrob Agents Chemother 2019; 63:1692–18 [View Article]
    [Google Scholar]
  29. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata . Antimicrob Agents Chemother 2012; 56:4862–4869 [View Article]
    [Google Scholar]
  30. Limtong S, Kaewwichian R, Yongmanitchai W, Kawasaki H. Diversity of culturable yeasts in phylloplane of sugarcane in Thailand and their capability to produce indole-3-acetic acid. World J Microbiol Biotechnol 2014; 30:1785–1796 [View Article]
    [Google Scholar]
  31. Morales-López SE, Taverna CG, Bosco-Borgeat ME, Maldonado I, Vivot W et al. Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: first description of Candida nivariensis in Argentina. Mycopathologia 2016; 181:871–878 [View Article]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.000963
Loading
/content/journal/jmm/10.1099/jmm.0.000963
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error